Lucendi
Los Angeles, US · Delaware corporation
Founders & leadership
MB
Maxim BatalinExecutive Officer, Director
AO
Aydogan OzcanDirector
GH
Gilbert HakimDirector
Reported raises · per SEC filings
Form D private placements▶$1MraisedNov 2025 · 1 investors · Other TechnologyRule 506(b)
▶$1MraisedNov 2025 · 1 investors · Other Technology
Rule 506(b)Officers, directors & promoters on the filing
- Maxim BatalinExecutive Officer, Director
- Gilbert HakimDirector
- Aydogan OzcanDirector
- Offering amount
- $1M
- Amount sold
- $1M
- Minimum investment
- $1M
- First sale
- Oct 2025
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$1MraisedSep 2023 · 1 investors · Other TechnologyRule 506(b)
▶$1MraisedSep 2023 · 1 investors · Other Technology
Rule 506(b)Officers, directors & promoters on the filing
- Aydogan OzcanDirector
- Maxim BatalinExecutive Officer, Director
- Offering amount
- $1M
- Amount sold
- $1M
- Minimum investment
- $1M
- First sale
- Aug 2023
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 04, 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Non-dilutive funding · 8 SBIR/STTR awards
Federal grants — no equity taken| Agency | Phase | Year | Amount |
|---|---|---|---|
| National Science Foundation | Phase II | 2021 | $1M |
| Environmental Protection Agency (EPA) | Phase II | 2021 | $400K |
| Department of Energy | Phase II | 2020 | $1.1M |
| Environmental Protection Agency (EPA) | Phase I | 2020 | $100K |
| National Science Foundation | Phase I | 2019 | $224.9K |
| Department of Energy | Phase I | 2019 | $200K |
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2018 | $1.5M |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2017 | $224.8K |
Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.